Jupiter Topco LLC Acquires Shares of 226,000 Elanco Animal Health Incorporated $ELAN

Jupiter Topco LLC acquired a new position in Elanco Animal Health Incorporated (NYSE:ELAN) during the second quarter, HoldingsChannel reports. The fund acquired 226,000 shares of the company’s stock, valued at approximately $5,566,000.

Several other large investors also recently made changes to their positions in the business. NewEdge Advisors LLC increased its stake in shares of Elanco Animal Health by 133.7% in the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock valued at $25,000 after buying an additional 627 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Elanco Animal Health during the 2nd quarter worth about $38,000. Root Financial Partners LLC lifted its position in Elanco Animal Health by 50.7% during the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock worth $40,000 after buying an additional 592 shares in the last quarter. Uniplan Investment Counsel Inc. bought a new stake in Elanco Animal Health during the 4th quarter worth about $41,000. Finally, Bessemer Group Inc. grew its holdings in Elanco Animal Health by 33.2% during the 1st quarter. Bessemer Group Inc. now owns 2,105 shares of the company’s stock worth $50,000 after acquiring an additional 525 shares during the last quarter. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Price Performance

Shares of ELAN stock opened at $24.01 on Tuesday. The company has a quick ratio of 1.10, a current ratio of 2.05 and a debt-to-equity ratio of 0.58. Elanco Animal Health Incorporated has a 12-month low of $17.11 and a 12-month high of $27.98. The firm has a fifty day moving average of $24.62 and a 200-day moving average of $23.99. The firm has a market capitalization of $12.00 billion, a price-to-earnings ratio of -58.56, a price-to-earnings-growth ratio of 1.44 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, topping the consensus estimate of $0.27 by $0.07. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The business had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.31 billion. During the same quarter last year, the business posted $0.26 EPS. The firm’s revenue was up 10.2% compared to the same quarter last year. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, equities research analysts forecast that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current year.

Insider Buying and Selling at Elanco Animal Health

In other Elanco Animal Health news, Director Lawrence Erik Kurzius acquired 40,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The stock was acquired at an average cost of $23.40 per share, for a total transaction of $936,000.00. Following the transaction, the director owned 188,647 shares of the company’s stock, valued at $4,414,339.80. This trade represents a 26.91% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Shiv O’neill bought 3,998 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were acquired at an average cost of $23.58 per share, with a total value of $94,272.84. Following the completion of the purchase, the insider owned 87,832 shares in the company, valued at $2,071,078.56. This represents a 4.77% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 63,198 shares of company stock worth $1,473,109 over the last three months. Company insiders own 1.14% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on ELAN. UBS Group raised their price objective on shares of Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. JPMorgan Chase & Co. increased their price target on shares of Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Piper Sandler reissued an “overweight” rating on shares of Elanco Animal Health in a report on Monday, June 29th. Morgan Stanley boosted their price objective on shares of Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 22nd. Finally, Weiss Ratings downgraded Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a report on Thursday, August 20th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Elanco Animal Health currently has a consensus rating of “Moderate Buy” and an average price target of $29.09.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.